US 7,449,196 B2
Anti tumor compositions and methods of use
Robert Sabin, P.O. Box 332, Goosedown Estate, Mill Neck, N.Y. 11765 (US)
Filed on Jul. 09, 2004, as Appl. No. 10/888,576.
Prior Publication US 2006/0008535 A1, Jan. 12, 2006
Int. Cl. A61K 9/127 (2006.01); A61K 31/295 (2006.01); A61K 33/34 (2006.01); A61K 33/26 (2006.01); A61K 31/30 (2006.01); A61F 13/00 (2006.01); A01N 59/20 (2006.01); A01N 59/16 (2006.01); A01N 55/02 (2006.01); A01N 25/26 (2006.01); A01N 25/28 (2006.01)
U.S. Cl. 424—422  [424/417; 424/418; 424/450; 424/493; 424/630; 424/646; 514/499; 514/502] 25 Claims
 
1. A method for treating cancer, cell proliferating diseases, solid tumors, liquid tumors, myelodysplasia disorders, hyper proliferative disorders, plasma cell dyscrasias and metastatic diseases in a patient comprising: forming a colloidal solution composition having a broad spectrum of anti-neoplastic properties, said composition having a core of at least a biologically acceptable copper compound, wherein said copper compound is a fixed copper compound selected from the group consisting of cupric hydroxide, copper oxide, copper oxychloride, cupric carbonate basic, copper sulfate basic, cuprous oxide, cupric hydroxide-iron hydroxide, copper-iron oxide, cupric citrate, cupric phosphate, cuprobam, indigo copper, minerals brochantite, langite, malachite, cornetite, libethenite, pseudolibethenite, pseudo-malachite, antlerite, covellite, marshite, cuprite, chalcocite, Rogojski's salt, brochantite, hydrocyanite, nantokite and dolerophane, said core being encapsulated, encoated, adsorbed, complexed or bound in at least one of a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof, and a pharmaceutically acceptable carrier; said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting cancer cells, cell proliferating disease cells, solid tumor cells, liquid tumor cells, myelodisplasia cells, hyper proliferative disorder cells, plasma cell dyscrasias cells or metastatic disease cells, and preventing immediate chemical interaction of the core with the surrounding environment; and administering the colloidal solution composition to a patient.